Robins Kaplan Adds Wilson Sonsini Drug Patent Atty In NY
Jeffrey Hovden, who is joining the firm as a partner, focuses on such cases under the Hatch-Waxman Act and within the biotechnology industry with clients including generics makers and name-brand drugmakers. The firm announced the addition of Hovden on June 25.
Ronald J. Schutz, the chairman of...
To view the full article, register now.